Everest Medicines Signs Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited
Accelerates Asia Pacific expansion by acquiring a ready-built regional commercial platform with 14 marketed chronic disease products Aggregate consideration of USD250,000,000 (approximately RMB1,721,650,000), payable in three installments Delivers...
Everest Medicines Enters into Letter of Intent with Hasten Biopharmaceuticals (Asia) Limited
SHANGHAI, March 18, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics,...